Description: Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Home Page: www.recursion.com
RXRX Technical Analysis
41 South Rio Grande Street
Salt Lake City,
UT
84101
United States
Phone:
385 269 0203
Officers
| Name | Title |
|---|---|
| Dr. Christopher C. Gibson Ph.D. | Co-Founder, CEO & Director |
| Ms. Tina Marriott Larson | COO & Pres |
| Dr. Blake C. Borgeson Ph.D. | Co-Founder & Director |
| Dr. Michael Secora Ph.D. | Chief Financial Officer |
| Dr. Shafique Virani M.D. | Interim Chief Medical Officer & Chief Bus. Officer |
| Kevin Leggat | VP of Fin. & Accounting |
| Mr. Benjamin Mabey M.S. | Chief Technology Officer |
| Mr. Jared Allenbach | Sr. Director of Investor Relations |
| Ms. Louisa Daniels J.D., M.B.A. | Chief Legal Officer & Gen. Counsel |
| Mr. Ryan Kelly | Chief Communications Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.46 |
| Price-to-Sales TTM: | 55.9421 |
| IPO Date: | 2021-04-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 400 |